SLC5A2 and heart failure: The therapeutic benefit of SGLT2 inhibitors in heart failure was first signaled in the EMPA-REG trial, which reported a significant reduction in heart failure hospitalizations by 35% (HR 0.65; 95% CI, 0.5–0.85) in the empagliflozin arm as a secondary outcome [6].